Work

Clinical safety of the selective PKC-β inhibitor, ruboxistaurin

Year: 2006

Type: review

Source: Expert Opinion on Drug Safety

DOI: 10.1517/14740338.5.6.835

Authors: Janet B McGill, George L King, Paul H Berg, Karen L Price, Keri A Kles, Edward J Bastyr, David L Hyslop

Institutions: Washington University in St. Louis, Joslin Diabetes Center, Harvard University, Eli Lilly (United States), Indiana University School of Medicine

Language: English

Topic: Pharmacovigilance and Adverse Drug Reactions

Subfield: Toxicology

Field: Pharmacology, Toxicology and Pharmaceutics

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: Eli Lilly and Company

OpenAlex ID: W2108059892

FWCI: 1.243

Cites: 33

Cited by: 48

Related to: 10